Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus
Introduction. This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients who fulfilled both the 2010 ACR/EULAR criteria for RA classification and the...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/697525 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551768833130496 |
|---|---|
| author | Kei Ikeda Yoshie Sanayama Sohei Makita Junichi Hosokawa Mieko Yamagata Daiki Nakagomi Katsuhiko Takabayashi Hiroshi Nakajima |
| author_facet | Kei Ikeda Yoshie Sanayama Sohei Makita Junichi Hosokawa Mieko Yamagata Daiki Nakagomi Katsuhiko Takabayashi Hiroshi Nakajima |
| author_sort | Kei Ikeda |
| collection | DOAJ |
| description | Introduction. This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients who fulfilled both the 2010 ACR/EULAR criteria for RA classification and the 1997 ACR revised criteria for classification of SLE and received abatacept treatment for arthritis were retrospectively studied. Results. Six rhupus patients who fulfilled the inclusion criteria above were identified. All patients had active arthritis despite receiving antirheumatic drugs including methotrexate when abatacept was initiated. Clinical Disease Activity Index (CDAI) significantly decreased between baseline and 12 weeks () and remained low through 24 weeks. All patients achieved either a good or moderate response according to the EULAR response criteria at 24 weeks. Health Assessment Questionnaire-Disability Index (HAQ-DI) also significantly decreased between baseline and 24 weeks (). In addition, the levels of immunoglobulin G and anti-DNA antibody significantly decreased between baseline and 24 weeks ( and , resp.). Conclusions. Treatment with abatacept is likely to be efficacious in patients with rhupus whose arthritis is refractory to methotrexate. In addition, abatacept may have a moderate effect on abnormal antibody production in rhupus patients. |
| format | Article |
| id | doaj-art-e5e13363edb74fa9a2dfd4cf48c7585b |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-e5e13363edb74fa9a2dfd4cf48c7585b2025-02-03T06:00:45ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/697525697525Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus ErythematosusKei Ikeda0Yoshie Sanayama1Sohei Makita2Junichi Hosokawa3Mieko Yamagata4Daiki Nakagomi5Katsuhiko Takabayashi6Hiroshi Nakajima7Department of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanDepartment of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JapanIntroduction. This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients who fulfilled both the 2010 ACR/EULAR criteria for RA classification and the 1997 ACR revised criteria for classification of SLE and received abatacept treatment for arthritis were retrospectively studied. Results. Six rhupus patients who fulfilled the inclusion criteria above were identified. All patients had active arthritis despite receiving antirheumatic drugs including methotrexate when abatacept was initiated. Clinical Disease Activity Index (CDAI) significantly decreased between baseline and 12 weeks () and remained low through 24 weeks. All patients achieved either a good or moderate response according to the EULAR response criteria at 24 weeks. Health Assessment Questionnaire-Disability Index (HAQ-DI) also significantly decreased between baseline and 24 weeks (). In addition, the levels of immunoglobulin G and anti-DNA antibody significantly decreased between baseline and 24 weeks ( and , resp.). Conclusions. Treatment with abatacept is likely to be efficacious in patients with rhupus whose arthritis is refractory to methotrexate. In addition, abatacept may have a moderate effect on abnormal antibody production in rhupus patients.http://dx.doi.org/10.1155/2013/697525 |
| spellingShingle | Kei Ikeda Yoshie Sanayama Sohei Makita Junichi Hosokawa Mieko Yamagata Daiki Nakagomi Katsuhiko Takabayashi Hiroshi Nakajima Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus Clinical and Developmental Immunology |
| title | Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus |
| title_full | Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus |
| title_fullStr | Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus |
| title_full_unstemmed | Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus |
| title_short | Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus |
| title_sort | efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus |
| url | http://dx.doi.org/10.1155/2013/697525 |
| work_keys_str_mv | AT keiikeda efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT yoshiesanayama efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT soheimakita efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT junichihosokawa efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT miekoyamagata efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT daikinakagomi efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT katsuhikotakabayashi efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus AT hiroshinakajima efficacyofabataceptforarthritisinpatientswithanoverlapsyndromebetweenrheumatoidarthritisandsystemiclupuserythematosus |